(13:00 GMT) Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital
DO Dow Jones Newswires Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital 6/30/2026, 09:00 PM GMT+8 Dow Jones Newswires AR ARWR (13:00 GMT) Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital Market News Dow Jones Newswires Arrowhead Pharmaceuticals Price Target Maintained With a $100.00/Share by HC Wainwright & Co. TradingView Key facts: Arrowhead plozasiran lowers triglycerides; REDEMPLO launched Quartr ARWR: Multiple late-stage RNAi programs target major unmet needs in lipid disorders, with key data ahead Quartr ARWR: Late-stage RNAi therapies show strong efficacy and safety, with major data readouts due in 2026
